Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.
JAAD Int
; 2: 62-75, 2021 Mar.
Article
em En
| MEDLINE
| ID: mdl-34409355
ABSTRACT
BACKGROUND:
Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions.OBJECTIVE:
To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction.METHODS:
This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry.RESULTS:
Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively.LIMITATIONS:
Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment.CONCLUSION:
Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
JAAD Int
Ano de publicação:
2021
Tipo de documento:
Article